Skip to main content
. 2021 Dec 22;11:739707. doi: 10.3389/fcimb.2021.739707

Table 2.

Major references connecting the gut microbiome with therapeutic agents for GD/GO.

Year Study Type Therapeutic Agent Subjects References
2020 Experimental PTU Adult male SD rat Shin et al. (2020)
2020 Experimental PTU/MMI Adult female SD rat Sun et al. (2020)
2020 Clinical PTU/MMI GD patient Sun et al. (2020)
2021 Clinical MMI GD patient Chen et al. (2021)
2021 Clinical MMI GD patient Huo et al. (2021)
2011 Experimental Stress (increased steroid) Mouse Bailey et al. (2011)
2018 Experimental GCs Bird Noguera et al. (2018)
2019 Clinical GCs Patient with GC-induced obesity Qiu et al. (2019)
2020 Experimental GCs (short term) Mouse Zhao et al. (2020)
2020 Experimental GCs (long term) Mouse Schepper et al. (2020)
2021 Clinical AZA Crohn’s disease patient Effenberger et al. (2021)
2018 Experimental MMF Mouse Flannigan et al. (2018)
2021 Experimental MMF Spontaneously hypertensive rat (SHR) Robles-Vera et al. (2021)
2019 Clinical Anti-TNF-α antibody Crohn’s disease patient Yilmaz et al. (2019)
2021 Clinical Anti-TNF-α antibody Enteropathic arthritis patient Ditto et al. (2021)
2021 Clinical Anti-TNF-α antibody Crohn’s disease patient Effenberger et al. (2021)

AZA, azathioprine; GD, Graves’ disease; GCs, glucocorticoids; GO, Graves’ orbitopathy; MMI, methimazole; MMF, mycophenolate mofetil; PTU, propylthiouracil; TNF-α, antitumor necrosis factor-α.